Targeting progression in MS (PPMS+SPMS)
Targeting progression in MS (PPMS+SPMS)
https://www.nature.com/articles/s41582-018-0127-3
In 2018, the distinguishing pathological features of white matter lesions in patients with progressive multiple sclerosis (MS) were refined, and serological and MRI biomarkers of clinical worsening and evolution to progressive MS were identified. We also saw therapeutic advances in progressive MS with the emergence of new neuroprotective strategies and putative markers of neurodegeneration.
Key advances:
A pathological study showed that substantial white matter lesion activity, in the form of mixed active–inactive, smouldering and slowly expanding lesions, persists and correlates with disease severity in patients with long-standing progressive multiple sclerosis (MS)1.
Levels of serum neurofilament light chain, a marker of neuroaxonal damage, were found to be higher in progressive MS than in relapsing MS, to correlate with current and future clinical disability, and to predict accelerated brain and spinal cord atrophy4.
In patients with relapse-onset MS, a high cortical lesion count at disease onset predicted conversion to secondary progressive MS5, and in patients with primary progressive MS, baseline grey matter damage was predictive of clinical worsening after 15 years6.
Integration of MRI measures into the clinical evaluation of patients with MS would allow earlier prognostication of long-term clinical outcomes6, leading to possible improvements in treatment decision-making and optimization of overall costs.
In a phase II trial in patients with progressive MS, ibudilast treatment was associated with slower progression of brain atrophy but also had some adverse effects10; this study provides the impetus for future trials of neuroprotection in progressive MS.
-
- Similar Topics
- Replies
- Views
- Last post
-
-
PPMS and SPMS may be different
by frodo » Sun Aug 11, 2019 3:53 am » in MS Etiology and Pathogenesis - 0 Replies
- 912 Views
-
Last post by frodo
Sun Aug 11, 2019 3:53 am
-
-
-
lipids differentiate PPMS and SPMS
by frodo » Fri Oct 02, 2020 4:47 am » in MS Etiology and Pathogenesis - 0 Replies
- 230 Views
-
Last post by frodo
Fri Oct 02, 2020 4:47 am
-
-
-
PPMS & SPMS are qualitatively indistinguishable
by NHE » Sun Jan 03, 2021 2:38 am » in General Discussion - 3 Replies
- 135 Views
-
Last post by frodo
Thu Jan 14, 2021 9:30 pm
-
-
-
retinal layer atrophy in PPMS/SPMS
by frodo » Fri Apr 17, 2020 1:42 am » in MS Etiology and Pathogenesis - 0 Replies
- 236 Views
-
Last post by frodo
Fri Apr 17, 2020 1:42 am
-
-
-
CXCR6: Targeting a rogue T cell prevents and reverses multiple sclerosis in mice
by NHE » Sat Oct 05, 2019 4:07 pm » in General Discussion - 3 Replies
- 801 Views
-
Last post by NHE
Thu Oct 17, 2019 10:22 am
-
-
- 0 Replies
- 403 Views
-
Last post by robbie
Wed Dec 18, 2019 2:47 pm
-
- 0 Replies
- 215 Views
-
Last post by frodo
Mon May 11, 2020 3:44 am
-
- 7 Replies
- 1302 Views
-
Last post by Jaded
Thu Oct 10, 2019 9:24 am
-
-
Does anyone have an experience with Ocrevus that worsens progression?
by motivation » Wed Jul 08, 2020 7:25 pm » in Ocrevus (Ocrelizumab) - 4 Replies
- 711 Views
-
Last post by HarbourBoy
Thu Jul 23, 2020 4:43 am
-